ArticleScience advances2026
Quantum-elevated chiral discrimination for biomolecules.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chiral discrimination of enantiomeric biomolecules is vital in chemistry, biology, and medicine. Conventional methods, relying on circularly polarized light, face weak chiroptical signals and potential photodamage. Despite extensive efforts to improve sensitivity under low-photon exposure, classical chiral probes remain fundamentally bound by the shot noise limit due to quantum fluctuations. To beat these limitations, we demonstrate quantum-elevated chiral discrimination using continuous-variable polarization-entangled states as moderate-photon flux, high-sensitivity, quantum noise-squeezed chiral probes. We achieve a 5-decibel improvement beyond the shot noise limit in distinguishing l- and d-amino acids in liquid phase. This nondestructive, biocompatible protocol enables high-sensitivity chiral analysis, with broad implications for drug development, biochemical research, environmental monitoring, and asymmetric synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.